-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

1565 Resistance to FLT3 Inhibitors in FLT3-Mutated AML Is Associated with CD45RA+CD200- leukemic Cells and Can be Overcome By Combination with SMAC Mimetics

Program: Oral and Poster Abstracts
Session: 618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Poster I
Hematology Disease Topics & Pathways:
Combination therapy, AML, Acute Myeloid Malignancies, Diseases, Treatment Considerations, Myeloid Malignancies
Saturday, December 7, 2024, 5:30 PM-7:30 PM

Nona Struyf1*, Henrik Gezelius, PhD2*, Anders Lundmark3*, Chiara Barizza1*, Hidde Ploeger1*, Lucía Rico Pizarro1*, Mattias Vesterlund, PhD, MSc1*, Georgios Mermelekas1*, Albin Osterroos, MD4*, Anna Bohlin5*, Sofia Bengtzén6*, Kerstin Hamberg Levedahl7*, Rozbeh Jafari, PhD1*, Lukas M Orre1*, Janne Lehtiö, PhD8*, Päivi Östling1*, Brinton Seashore-Ludlow1*, Jessica Nordlund, PhD3*, Soren Lehmann, MD, PhD4,9*, Olli Kallioniemi1,10* and Tom Erkers1*

1Department of Oncology-Pathology and Science for Life Laboratory, Karolinska Institute, Stockholm, Sweden
2Med, Uppsala University, Uppsala, Sweden
3Department of Medical Sciences and Science for Life Laboratory, Uppsala University, Uppsala, Sweden
4Department of Medical Sciences, Hematology, Uppsala University, Uppsala, Sweden
5Department of Medicine, Center for Hematology and Regenerative Medicine, Karolinska Institutet, Stockholm, Sweden
6Department of Medicine, Center for Hematology and Regenerative Medicine, Karolinska Institute, Stockholm, Sweden
7Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden
8Department of Oncology-Pathology and Science for Life Laboratory, Karolinska Institutet, Stockholm, Sweden
9Center for Hematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institute, Stockholm, Sweden
10FIMM, University of Helsinki, Helsinki, Finland

Acute myeloid leukemia (AML) is a disease caused by abnormal proliferations of myeloid progenitor cells in the bone marrow. About 25-30% of AML patients have a mutation in the FLT3 gene, which is associated with a poor prognosis. Although FLT3-inhibitors (FLT3i) that can target this mutation are clinically approved, approximately 40% of FLT3mut patients do not respond to FLT3i.

In this study we performed high-throughput functional ex vivo drug testing (n=528) in 63 FLT3mut patients, with paired MS-proteomics (n=20), RNA-seq (n=20), plasma proteome (n=16), spatial single-cell proteomics (n=6) and mass cytometry (n=3) data with the aim to uncover the functional and molecular landscape linked to FLT3i response.

First, we compared clinical and ex vivo response to FLT3i (midostaurin) to determine the clinical predictability of our ex vivo drug testing. All five ex vivo responders had a complete remission (CR) after first treatment with conventional induction therapy and midostaurin, while four out of five non-responders eventually relapsed or had no CR.

Furthermore, non-responders had an increased immune activation and displayed immature stem cell phenotypes, as well as decreased expression of surface markers associated with mature myeloid cells (e.g., CD64, CD11c, CD33) compared to responders. Moreover, soluble CD40, CD244, PD-L1, CD4, and IL12RB1 were increased in responders, indicating an immune suppressive environment consistent with RNA and protein data. Surprisingly, the T cell receptor proteins CD200 and CD45RA were found to be increased in FLT3i responders and non-responders, respectively.

None of the other 527 drugs tested ex vivo were more effective in the non-responder group, including other FLT3i. Thus, we performed drug combination screening on FLT3mut and FLT3i resistant cell lines and patient cells to identify effective drug combinations. Combinatorial drug screening in resistant FLT3mut cells revealed an increase in drug sensitivity to apoptotic modulators, as well as PI3K/AKT inhibitors in combination with midostaurin. Subsequent validation confirmed synergy between the midostaurin and the SMAC-mimetics birinapant and LCL161, while the BH3 mimetic venetoclax and the PI3K inhibitor idelalisib only showed an additive effect.

Our data shows specific differences in myeloid maturation and LSC (Leukemic Stem Cell) phenotype between midostaurin responders and non-responders, together with a potential functional shift in cell signaling in immune signaling and anti-apoptotic pathways. Moreover, ex vivo drug testing data demonstrates that while there is less overall sensitivity to drug treatment in non-responders, combination therapies including apoptotic modulators such as the SMAC mimetics could overcome FLT3i resistance and improve FLT3mut patient outcomes.

Disclosures: Lehmann: Servier: Membership on an entity's Board of Directors or advisory committees; Rarity: Membership on an entity's Board of Directors or advisory committees; Pfizer: Membership on an entity's Board of Directors or advisory committees; Abbvie: Membership on an entity's Board of Directors or advisory committees. Kallioniemi: Sartar Therapeutics: Other: Co-founder and stockholder; Vysis-Abbot: Patents & Royalties.

*signifies non-member of ASH